| C27 | Early predictors of seroconversion among enrolees in a PrEP program in Brazil, Mexico and Peru ' the IMPREP Demonstration study | On-demand oral abstract session | PrEP |
| C27 | Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDF | On-demand oral abstract session | PrEP |
| C27 | Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis | On-demand oral abstract session | PrEP |
| C27 | Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP | On-demand oral abstract session | PrEP |
| C27 | SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-Sero | On-demand oral abstract session | PrEP |
| C27 | Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019 ' June 2020 | On-demand oral abstract session | PrEP |
| C27 | Uptake of oral pre-exposure prophylaxis for HIV infection among men who have sex with men and transgender: lessons learned during the SARS-CoV-2 pandemic from the first PrEP project in Myanmar | On-demand oral abstract session | PrEP |
| C27 | HIV risk behaviors among retail pharmacy clients seeking sexual and reproductive health services in Kenya | On-demand oral abstract session | PrEP |
| C27 | STI incidence among participants in the HIV Pre-exposure Prophylaxis (PrEP) impact trial in England | On-demand oral abstract session | PrEP |
| C27 | Safety and pharmacokinetics of oral islatravir once monthly for HIV pre-exposure prophylaxis (PrEP): week 24 analysis of a phase 2a trial | Oral abstract session with live Q&A | PrEP |